MAI Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

MAI Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-526	Closed	-$301	–	4661
2026 Q1	$301	Hold	526	–	–	﹤0.01%	4531
2025 Q4	$349	Hold	526	–	–	﹤0.01%	3930
2025 Q3	$1.87K	Hold	526	–	–	﹤0.01%	3323
2025 Q2	$1.05K	Sell	526 -50	-9%	-$114	﹤0.01%	3609
2025 Q1	$1.44K	Sell	576 -33	-5%	-$93	﹤0.01%	3038
2024 Q4	$1.8K	Buy	+609	New	+$1.71K	﹤0.01%	3050
2023 Q2	–	Sell	-19,498	Closed	-$72.9K	–	1127
2023 Q1	$72.9K	Sell	19,498 -1,093	-5%	-$5.73K	﹤0.01%	997
2022 Q4	$63.6K	Sell	20,591 -41,197	-67%	-$155K	﹤0.01%	965
2022 Q3	$282K	Sell	61,788 -26,925	-30%	-$267K	0.01%	716
2022 Q2	$2.34M	Buy	+88,713	New	+$3.13M	0.04%	232

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

MAI Capital Management's VTGN Position: Q2 2026 in Review

MAI Capital Management sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 526 shares — an estimated $301 sold.

MAI Capital Management first reported a position in VTGN in Q2 2022 and held it in 10 quarters. The position peaked at $2.34M in Q2 2022. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

MAI Capital Management reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 526 VistaGen Therapeutics shares in Q2 2026, an estimated $301.
MAI Capital Management first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 10 quarters.
MAI Capital Management's VistaGen Therapeutics position peaked at $2.34M in Q2 2022.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.